keyword
MENU ▼
Read by QxMD icon Read
search

neutropenia febrile

keyword
https://www.readbyqxmd.com/read/28345833/efficacy-and-toxicity-of-low-dose-versus-conventional-dose-chemotherapy-for-malignant-tumors-a-meta-analysis-of-6-randomized-controlled-trials
#1
Xianhe Xie, Yupeng Wu, Shuimei Luo, Haitao Yang, Lina Li, Sijing Zhou, Ruifen Shen, Heng Lin
Low-dose chemotherapy has emerged as a new strategy for control of cancer. However, there is a controversy as to whether low-dose chemotherapy is an effective way to manage many human malignancies. To shed light on this controversy, we performed a meta-analysis of relative merits between low-dose and conventional-dose chemotherapy in different carcinomas. Studies published before February 29, 2016 were reviewed for the meta-analysis and selected according to defined criteria. The effect levels of low-dose chemotherapy regarding overall survival (OS), progression-free survival (PFS) and severe adverse events (SAEs) (Grade≥3) were calculated as risk ratios (ORs) or adjusted hazard ratios (HRs)...
February 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28343975/trastuzumab-emtansine-versus-taxane-use-for-previously-treated-her2-positive-locally-advanced-or-metastatic-gastric-or-gastro-oesophageal-junction-adenocarcinoma-gatsby-an-international-randomised-open-label-adaptive-phase-2-3-study
#2
Peter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara, Gail D Lewis Phillips, Tina van der Horst, Marie-Laurence Harle-Yge, Betsy L Althaus, Yoon-Koo Kang
BACKGROUND: Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is no established therapy in the second-line setting. In GATSBY, we examined the efficacy and tolerability of trastuzumab emtansine in patients previously treated for HER2-positive advanced gastric cancer (unresectable, locally advanced, or metastatic gastric cancer, including adenocarcinoma of the gastro-oesophageal junction). METHODS: This is the final analysis from GATSBY, a randomised, open-label, adaptive, phase 2/3 study, done at 107 centres (28 countries worldwide)...
March 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28343905/the-dana-farber-consortium-protocol-for-the-treatment-of-adolescents-and-young-adults-with-acute-lymphoblastic-leukemia-a-single-institution-experience-in-saudi-arabia
#3
Amal S Alabdulwahab, Hussein G Elsayed, Mohamed A Sherisher, Wafa M Elbjeirami, Nelly Alieldin
BACKGROUND: Recent retrospective analyses and phase II trials have shown differential outcomes in adolescents and young adults when treated with pediatric compared with adult protocols. The aim of this study was to evaluate the efficacy and toxicity of the Dana Farber Consortium Protocol (DFCP) in Saudi young adults diagnosed with de novo acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: In this retrospective study we included 38 patients with de novo ALL who presented to King Abdulla Medical City in the period from June 2010 to March 2015 and received the DFCP (Princess Margret modified version)...
February 16, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28341958/randomized-phase-ii-study-comparing-weekly-docetaxel-cisplatin-vs-gemcitabine-cisplatin-in-elderly-or-poor-performance-status-patients-with-advanced-non-small-cell-lung-cancer
#4
JoungSoon Jang, Hoon-Kyo Kim, Byoung Chul Cho, Kyung Hee Lee, Hwan-Jung Yun, In Sook Woo, Hong Suk Song, Hun-Mo Ryoo, Chi-Hong Kim, Der-Sheng Sun, Jong Wook Shin
BACKGROUND: Docetaxel/cisplatin (DP) and gemcitabine/cisplatin (GP) are standard treatment regimens for advanced non-small cell lung cancer (NSCLC). In spite of potent efficacy, the conventional 1-day DP is regarded as having more toxicity as compared with GP. There is increasing interest in a biweekly split administration of DP to reduce its toxicity. Hypothesis was that first-line biweekly DP is as safe as GP in the elderly or poor performance status (PS) patients. METHODS: Chemotherapy-naïve patients with advanced NSCLC (IIIB/IV) who were elderly (65<) or PS (ECOG 2) were randomized to DP or GP arm by balancing for ECOG (0-1 vs...
March 24, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28335887/trastuzumab-in-combination-with-weekly-paclitaxel-and-carboplatin-as-neo-adjuvant-treatment-for-her2-positive-breast-cancer-the-train-study
#5
Mette S van Ramshorst, Erik van Werkhoven, Ingrid A M Mandjes, Margaret Schot, Jelle Wesseling, Marie-Jeanne T F D Vrancken Peeters, Jetske M Meerum Terwogt, Monique E M Bos, Hendrika M Oosterkamp, Sjoerd Rodenhuis, Sabine C Linn, Gabe S Sonke
AIM: To determine the efficacy and safety of an anthracycline-free neo-adjuvant regimen consisting of weekly paclitaxel, carboplatin and trastuzumab in HER2-positive breast cancer. PATIENTS AND METHODS: Patients with stage II or III HER2-positive breast cancer received weekly paclitaxel ([P], 70 mg/m(2)), trastuzumab ([T], 2 mg/kg, loading dose 4 mg/kg) and carboplatin ([C], AUC = 3 mg ml(-1) min) for 24 weeks. In weeks 7, 8, 15, 16, 23 and 24, trastuzumab was administered without chemotherapy...
March 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28324747/optimal-dose-reduction-of-folfirinox-for-preserving-tumour-response-in-advanced-pancreatic-cancer-using-cumulative-relative-dose-intensity
#6
Jong-Chan Lee, Jin Won Kim, Soyeon Ahn, Hyoung Woo Kim, Jongchan Lee, Young Hoon Kim, Kyu-Hyun Paik, Jaihwan Kim, Jin-Hyeok Hwang
BACKGROUND: FOLFIRINOX has increased efficacy but also toxicity. Despite various modified FOLFIRINOX regimens, how much reduction is acceptable remains unclear. This study aimed to find the optimal relative dose intensity (RDI, %) of FOLFIRINOX that preserves tumour responses in patients with advanced pancreatic cancer (PC). METHODS: We reviewed 201 patients with PC treated with first-line FOLFIRINOX during 2012-2015. We established a modified Hryniuk model (http://www...
March 16, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28323339/adjuvant-radiation-therapy-androgen-deprivation-and-docetaxel-for-high-risk-prostate-cancer-postprostatectomy-results-of-nrg-oncology-rtog-study-0621
#7
Mark D Hurwitz, Jonathan Harris, Oliver Sartor, Ying Xiao, Bobby Shayegan, Paul W Sperduto, Kasra R Badiozamani, Colleen A F Lawton, Eric M Horwitz, Jeff M Michalski, Kevin Roof, David C Beyer, Qiang Zhang, Howard M Sandler
BACKGROUND: Phase 3 trials have demonstrated a benefit from adjuvant radiation therapy (ART) for men who have adverse factors at radical prostatectomy (RP). However, some patients have a high risk of progression despite ART. The role of systemic therapy with ART in this high-risk group remains to be defined. METHODS: Patients who had either a post-RP prostate-specific antigen (PSA) nadir > 0.2 ng/mL and a Gleason score ≥7 or a PSA nadir ≤0.2 ng/mL, a Gleason score ≥8, and a pathologic tumor (pT) classification ≥ pT3 received 6 months of androgen-deprivation therapy (ADT) plus radiotherapy and 6 cycles of docetaxel...
March 21, 2017: Cancer
https://www.readbyqxmd.com/read/28314319/multicenter-phase-ii-clinical-trial-of-genexol-pm%C3%A2-with-gemcitabine-in-advanced-biliary-tract-cancer
#8
Jin Young Kim, Young Rok DO, Hong Suk Song, Yoon Young Cho, Hun Mo Ryoo, Sung Hwa Bae, Jong Gwang Kim, Yee Soo Chae, Byung Woog Kang, Jin Ho Baek, Min Kyoung Kim, Kyung Hee Lee, Keonuk Park
This multicenter phase II clinical trial was designed to evaluate the efficacy and safety of weekly Genexol-PM® and gemcitabine combination chemotherapy in patients with unresectable or metastatic biliary tract cancer. PATIENTS AND METHODS: Patients received 100 mg/m(2) Genexol-PM® and 1,000 mg/m(2) gemcitabine intravenously on days 1 and 8 every 21 days. RESULTS: Out of 39 patients, there were 10 partial responses (25.6%) and 18 with stable diseases (46.2%) were confirmed with median response duration 4...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28303057/retrospective-survey-and-evaluation-of-first-line-antibiotics-for-chemotherapy-induced-febrile-neutropenia-in-patients-with-acute-myeloid-leukemia
#9
Naoki Mukoyama, Marie Nakashima, Koichi Miyamura, Akira Yoshimi, Yukihiro Noda, Kazuhiro Mori
Patients with acute leukemia are susceptible to chemotherapy-induced severe myelosuppression, and therefore are at a high risk for febrile neutropenia (FN). In such cases, the use of broad-spectrum antibiotics such as fourth-generation cephalosporins and carbapenems is recommended as first-line antimicrobial treatment; however, the effectiveness of these agents in patients with acute myeloid leukemia (AML) has not been investigated in detail. We retrospectively examined and evaluated the effectiveness of first-line antibiotic treatment regimens for chemotherapy-induced FN in patients with AML in Japanese Red Cross Nagoya Daiichi Hospital...
February 2017: Nagoya Journal of Medical Science
https://www.readbyqxmd.com/read/28292998/-clinical-study-to-determine-the-dose-intensity-of-bep-chemotherapy-for-ovarian-malignant-germ-cell-tumors
#10
Shinya Kusumoto, Hiroyuki Naito, Kunitomo Imazu, Itsuka Kai, Aki Hamasaki, Yoshie Kazusa, Yumiko Nakashima, Miho Kodama, Masatoshi Kumagai, Katsunori Ueda
A standard regimen for ovarian malignant germ cell tumors is bleomycin, etoposide, cisplatin(BEP)chemotherapy. Adherence to a treatment schedule of every 21 days has been reported to be important. However, the incidence of febrile neutropenia( FN)and the optimaluse of granulocyte-colony stimulating factor(G-CSF)are unclear because of the low incidence of ovarian malignant germ cell tumors. We experienced 2 cases of ovarian malignant germ cell tumors that received BEP therapy after fertility-conserving surgery...
March 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28291390/efficacy-and-safety-of-anti-trop-2-antibody-drug-conjugate-sacituzumab-govitecan-immu-132-in-heavily-pretreated-patients-with-metastatic-triple-negative-breast-cancer
#11
Aditya Bardia, Ingrid A Mayer, Jennifer R Diamond, Rebecca L Moroose, Steven J Isakoff, Alexander N Starodub, Nikita C Shah, Joyce O'Shaughnessy, Kevin Kalinsky, Michael Guarino, Vandana Abramson, Dejan Juric, Sara M Tolaney, Jordan Berlin, Wells A Messersmith, Allyson J Ocean, William A Wegener, Pius Maliakal, Robert M Sharkey, Serengulam V Govindan, David M Goldenberg, Linda T Vahdat
Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selective delivery of SN-38, the active metabolite of irinotecan. Patients and Methods We evaluated sacituzumab govitecan in a single-arm, multicenter trial in patients with relapsed/refractory metastatic TNBC who received a 10 mg/kg starting dose on days 1 and 8 of 21-day repeated cycles. The primary end points were safety and objective response rate; secondary end points were progression-free survival and overall survival...
March 14, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28289961/the-time-has-come-for-new-models-in-febrile-neutropenia-a-practical-demonstration-of-the-inadequacy-of-the-mascc-score
#12
A Carmona-Bayonas, P Jiménez-Fonseca, J Virizuela Echaburu, M Sánchez Cánovas, F Ayala de la Peña
Since its publication more than 15 years ago, the MASCC score has been internationally validated any number of times and recommended by most clinical practice guidelines for the management of febrile neutropenia (FN) around the world. We have used an empirical data-supported simulated scenario to demonstrate that, despite everything, the MASCC score is impractical as a basis for decision-making. A detailed analysis of reasons supporting the clinical irrelevance of this model is performed. First, seven of its eight variables are "innocent bystanders" that contribute little to selecting low-risk candidates for ambulatory management...
March 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28286615/detection-of-legionella-pneumophila-in-urine-and-serum-specimens-of-neutropenic-febrile-patients-with-haematological-malignancies
#13
Nastaran Farzi, Zahra Abrehdari-Tafreshi, Omid Zarei, Leili Chamani-Tabriz
Background: Legionella pneumophila (L. pneumophila) is a gram-negative bacterium which causes ‎Legionnaires' disease as well as Pontiac fever. The Legionella infections in patients suffering from ‎neutropenia- as a common complication of cancer chemotherapy- can distribute rapidly. We ‎aimed to detect of L. pneumophila in haematological malignancy suffering patients with ‎neutropenic fever by targeting the (macrophage infectivity potentiator) mip gene. Subjects andMethods: Serum and ‎urine specimens were obtained from 80 patients and presence of mip gene of L...
January 1, 2017: International Journal of Hematology-oncology and Stem Cell Research
https://www.readbyqxmd.com/read/28283282/custirsen-in-combination-with-docetaxel-and-prednisone-for-patients-with-metastatic-castration-resistant-prostate-cancer-synergy-trial-a-phase-3-multicentre-open-label-randomised-trial
#14
Kim N Chi, Celestia S Higano, Brent Blumenstein, Jean-Marc Ferrero, James Reeves, Susan Feyerabend, Gwenaelle Gravis, Axel S Merseburger, Arnulf Stenzl, Andries M Bergman, Som D Mukherjee, Pawel Zalewski, Fred Saad, Cindy Jacobs, Martin Gleave, Johann S de Bono
BACKGROUND: Clusterin is a chaperone protein associated with treatment resistance and upregulated by apoptotic stressors such as chemotherapy. Custirsen is a second-generation antisense oligonucleotide that inhibits clusterin production. The aim of the SYNERGY trial was to investigate the effect of custirsen in combination with docetaxel and prednisone on overall survival in patients with metastatic castration-resistant prostate cancer. METHODS: SYNERGY was a phase 3, multicentre, open-label, randomised trial set at 134 study centres in 12 countries...
March 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28283020/carbapenem-resistant-klebsiella-pneumoniae-in-high-risk-haematological-patients-factors-favouring-spread-risk-factors-and-outcome-of-carbapenem-resistant-klebsiella-pneumoniae-bacteremias
#15
Alessandra Micozzi, Giuseppe Gentile, Clara Minotti, Claudio Cartoni, Saveria Capria, Daniele Ballarò, Stefania Santilli, Emanuele Pacetti, Sara Grammatico, Giampaolo Bucaneve, Robin Foà
BACKGROUND: Carbapenem-resistant Klebsiella pneumoniae (CRKP) spread and infections in patients with haematological malignancies are a serious concern especially in endemic areas. Treatment failures and delay in appropriate therapy for CRKP infections are frequent and the mortality rate associated with CRKP bacteremia in neutropenic haematological patients is reported about 60%. METHODS: Haematological patients harboring CRKP hospitalized between February 2012 and May 2013 in an Italian Teaching hospital were examined...
March 10, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28283014/-fungemia-and-septic-arthritis-caused-by-saprochaete-capitata-in-a-patient-with-fanconi-aplastic-anemia-a-case-report
#16
Ömür Mustafa Parkan, Mustafa Altay Atalay, Ayşe Nedret Koç, Çiğdem Pala, Gonca Aydemir, Leylagül Kaynar
Saprochaete capitata (formerly known as Blastoschizomyces capitatus, Trichosporon capitatum, Geotrichum capitatum) is a rare but emerging yeast-like fungus. It is commonly found in environmental sources and can be isolated from skin, gastrointestinal system and respiratory tract of healthy individuals as well. It mainly infects patients with hematological malignancies such as acute myeloid leukemia (AML), especially in the presence of neutropenia; and mortality rates are high in those patients. Although the data about the in vitro antifungal susceptibility are limited, it is being reported that amphotericin B and voriconazole are more effective on S...
January 2017: Mikrobiyoloji Bülteni
https://www.readbyqxmd.com/read/28280972/pemetrexed-monotherapy-for-chemo-na%C3%A3-ve-elderly-aged-%C3%A2-80-patients-with-non-squamous-non-small-cell-lung-cancer-results-from-combined-analysis-of-two-single-arm-phase-ii-studies-hanshin002-and-003
#17
Akito Hata, Nobuyuki Katakami, Yoshihiro Hattori, Kosuke Tanaka, Shiro Fujita, Yoshikazu Kotani, Takashi Nishimura, Fumio Imamura, Soichiro Yokota, Miyako Satouchi, Kazuya Monden, Kojiro Otsuka, Akihiro Nishiyama, Kazuya Tsubouchi, Toshihiko Kaneda, Hiroshige Yoshioka, Satoshi Morita, Shunichi Negoro
PURPOSE: The aim of this retrospective study was to evaluate via combined analysis the efficacy and safety of pemetrexed monotherapy for chemo-naïve elderly patients aged ≥80 with non-squamous non-small cell lung cancer (NSCLC). METHODS: We conducted a combined analysis from two phase II studies of pemetrexed for chemo-naïve elderly (aged ≥75) (n = 47) and performance status 2 (n = 28) patients with advanced non-squamous NSCLC. Population aged ≥80 (80+ Group) was compared to those aged 70-79 (70's Group)...
March 9, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28279491/proposal-for-shorter-antibiotic-therapies
#18
C Wintenberger, B Guery, E Bonnet, B Castan, R Cohen, S Diamantis, P Lesprit, L Maulin, Y Péan, E Peju, L Piroth, J P Stahl, C Strady, E Varon, F Vuotto, R Gauzit
OBJECTIVES: Reducing antibiotic consumption has now become a major public health priority. Reducing treatment duration is one of the means to achieve this objective. Guidelines on the therapeutic management of the most frequent infections recommend ranges of treatment duration in the ratio of one to two. The Recommendation Group of the French Infectious Diseases Society (SPILF) was asked to collect literature data to then recommend the shortest treatment durations possible for various infections...
March 6, 2017: Médecine et Maladies Infectieuses
https://www.readbyqxmd.com/read/28278704/incidence-etiology-and-timing-of-infections-following-azacitidine-therapy-for-myelodysplastic-syndromes
#19
Jason A Trubiano, Michael Dickinson, Karin A Thursky, Timothy Spelman, John F Seymour, Monica A Slavin, Leon J Worth
We examine the infective complications occurring during azacitidine (AZA) therapy in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). A retrospective review of patients receiving ≥1 cycle of AZA for MDS or AML was performed. Patient demographics, infection prophylaxis/episodes and outcomes were evaluated. Sixty eight patients received 884 AZA cycles. Bacterial infections occurred in 25% of cycle-1 and 27% of cycle-2 AZA therapy. Febrile neutropenia complicated 5.3% of AZA cycles, bacteremia 2% and invasive Aspergillosis 0...
February 28, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28271398/optimizing-symptoms-and-management-of-febrile-neutropenia-among-cancer-patients-current-status-and-future-directions
#20
REVIEW
Xiao Jun Wang, Alexandre Chan
Febrile neutropenia (FN) is a common and serious complication among cancer patients undergoing myelosuppressive chemotherapy. FN should be treated as a medical emergency because it can lead to life-threatening complications if appropriate treatment is not initiated immediately. This study provides a critical review on the current management of FN and identifies possible directions to optimize FN management.
March 2017: Current Oncology Reports
keyword
keyword
51731
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"